학술논문
Post Covid-19 Cerebral Mucormycosis - A Neurosurgical Perspective
Document Type
Academic Journal
Source
European Journal of Molecular and Clinical Medicine. Summer 2021, Vol. 8 Issue 4, p2704, 9 p.
Subject
Language
English
Abstract
1. INTRODUCTION Fungal infections of the central nervous system, especially cerebral mucormycosis are rare (1) .It is usually not an independent disease, but a secondary opportunistic infectious disease caused by [...]
BACKGROUND - Fungal infections of the central nervous system, especially cerebral mucormycosis are rare. Usually, it is a secondary opportunistic infection than a primary infection of the brain. Recently there has been a rise in cerebral mucormycosis in the patients of COVID 19 due to various factors like impairment of barrier defense mechanisms and use of immunosuppressive medications like steroids for the treatment of COVID 19. The following observational study is conducted by the neurosurgery unit of the General surgery department at Gandhi Medical College Bhopal and its associated hospital. AIMS AND OBJECTIVES - The aim of this study was to determine the pattern of cerebral involvement of mucormycosis and the various associated factors in the patients of COVID 19 infection. MATERIALAND METHODS- This is an observational study conducted by the neurosurgery unit of the General surgery department of Gandhi medical college and associated Hamidia hospital Bhopal. Details of 55 patients who were treated in various departments of this hospital for post-COVID 19 mucormycosis infection with any kind of cerebral involvement are collected and analysed. The study was undertaken for the duration of 08 months from March 2021 to October 2021. KEYWORDS - Post-COVID 19 mucormycosis, cerebral mucormycosis, neurosurgical aspect of mucormycosis, a cerebral fungal infection. CONCLUSION - Mucormycosis is a rare opportunistic infection. The patients with COVID 19 infection are found to be more susceptible to this fungal infection because of impairment of barrier defense mechanism and the use of immunosuppressive medications like steroids and tocilizumab for the treatment of COVID 19 disease. Most patients who encountered mucormycosis were diabetic. Being vigilant in high-risk patients for this fungal infection can improve the quality of patient care and outcome.
BACKGROUND - Fungal infections of the central nervous system, especially cerebral mucormycosis are rare. Usually, it is a secondary opportunistic infection than a primary infection of the brain. Recently there has been a rise in cerebral mucormycosis in the patients of COVID 19 due to various factors like impairment of barrier defense mechanisms and use of immunosuppressive medications like steroids for the treatment of COVID 19. The following observational study is conducted by the neurosurgery unit of the General surgery department at Gandhi Medical College Bhopal and its associated hospital. AIMS AND OBJECTIVES - The aim of this study was to determine the pattern of cerebral involvement of mucormycosis and the various associated factors in the patients of COVID 19 infection. MATERIALAND METHODS- This is an observational study conducted by the neurosurgery unit of the General surgery department of Gandhi medical college and associated Hamidia hospital Bhopal. Details of 55 patients who were treated in various departments of this hospital for post-COVID 19 mucormycosis infection with any kind of cerebral involvement are collected and analysed. The study was undertaken for the duration of 08 months from March 2021 to October 2021. KEYWORDS - Post-COVID 19 mucormycosis, cerebral mucormycosis, neurosurgical aspect of mucormycosis, a cerebral fungal infection. CONCLUSION - Mucormycosis is a rare opportunistic infection. The patients with COVID 19 infection are found to be more susceptible to this fungal infection because of impairment of barrier defense mechanism and the use of immunosuppressive medications like steroids and tocilizumab for the treatment of COVID 19 disease. Most patients who encountered mucormycosis were diabetic. Being vigilant in high-risk patients for this fungal infection can improve the quality of patient care and outcome.